VIRACTA THERAPEUTICS INC (VIRX)
US92765F1084 - Common Stock
Tuesday's after hours session: top gainers and losers
Tuesday's after hours session: top gainers and losers
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell...
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024
VIRX stock results show that Viracta Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viracta Therapeutics (NASDAQ:VIRX) just reported results for the second quarter...
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?
Viracta Therapeutics stock is up on Wednesday alongside as VIRX investors react to its most recent earnings report and business updates.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2...
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth checking out on Tuesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning!
Viracta Therapeutics Announces New Employment Inducement Grants
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024
VIRX stock results show that Viracta Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viracta Therapeutics (NASDAQ:VIRX) just reported results for the first quarter ...
3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck
Although the concept of penny stocks under $1 is wildly speculative, these ideas could fly higher under the right circumstances.
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients...
VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023
VIRX stock results show that Viracta Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed...
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1,...
Viracta gets orphan drug status for Nana-val for EBV tumors (NASDAQ:VIRX)
Viracta Therapeutics (VIRX) has received FDA orphan drug designation for Nana-val in treatment of Epstein-Barr virus-positive solid tumors. Read more here.
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further...
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell...